IOncology

At ASCO GI 2025, Prof. Ying Yuan shared updated data from the BB+CAPOX Phase II trial, showing a median PFS of 25.3 months in liver-only RAS-mutant MSS mCRC. Prof. Kefeng Ding highlighted the potential of this combo to convert immune-cold tumors into responsive disease.

At the ASCO GI 2025 Symposium in San Francisco, experts from Peking University Cancer Hospital presented new data on SHR1701, a PD-L1/TGF-βR2 fusion protein. The Phase III results showed both survival benefits and a reduction in chemotherapy-induced myelosuppression in advanced gastric and GEJ cancers.

At the 2025 European Lung Cancer Conference (ELCC), Professor Benjamin Besse from the Gustave Roussy Institute presented a report titled “Less is More: De-escalation Strategies in Patient Management and Clinical Trials.” He emphasized that while de-escalation strategies for drug treatments are still being actively explored, clinical applications face challenges, such as insufficient research funding.

At the 2025 European Lung Cancer Conference (ELCC), Professor Antonio Passaro from the European Institute of Oncology (IEO), Italy, led a deep discussion during the controversy session on the topic, "Optimizing the first-line treatment of EGFR-mutant NSCLC: Has the time for TKI combinations arrived?"

The European Association of Urology (EAU) Annual Meeting is one of the most influential academic events in the global urology field, playing a crucial role in promoting innovation and optimizing…

The 19th St. Gallen Breast Cancer Conference (SGBCC 2025) took place from March 12–15, 2025, in Vienna, Austria. On the third day (March 14), Professor Cicero Urban, Bioethics and Scientific…

The 19th St.Gallen  Breast Cancer Conference (SGBCC 2025) was held from March 12–15, 2025, in the music capital of Vienna, Austria. The "Voice of China" session at this conference provided…

Published on February 10, 2025, in Cancer Cell, this international effort led by Carsten Denkert and colleagues investigates the dynamics of therapy-induced molecular heterogeneity in high-risk HR+/HER2− breast cancer, using…

In the treatment of low rectal cancer, the “watch and wait” strategy has sparked a compelling debate between organ preservation and radical resection. With the advancement of neoadjuvant therapies, some patients achieve clinical complete response (cCR) following chemoradiotherapy, opening the door to non-operative management and the possibility of avoiding a permanent stoma. However, concerns over local regrowth, subjective response assessment, and the psychological burden on patients continue to challenge the broader application of this approach.